Price movement over the last 24 hours
ADMA Biologics Inc vs Wolfspeed Inc — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Wolfspeed Inc trades at $34.77 (market cap $1.87B). The key difference: ADMA Biologics Inc and Wolfspeed Inc are close in size by market cap, and Wolfspeed Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | WOLF | |
|---|---|---|
Market Cap | $2.13B | $1.87B |
Sector | Health | Technology |
52-Week High | $20.38 | $73.68 |
52-Week Low | $7.60 | $1.19 |
Enterprise Value | $2.20B | $2.53B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Wolfspeed (WOLF) trades at $39.47, down 1.33% today, amid bearish technical signals and negative profitability metrics. The company shows strategic progress with AI data center revenue growth and key partnerships, though it faces significant financial challenges with negative gross margins and net losses. Technical indicators show the stock testing support levels with overall bearish momentum despite some neutral oscillators.
The outlook remains cautious with Wall Street divided (31.58% buy ratings) amid ongoing losses and competitive pressures. Near-term catalysts include the Q2 2026 earnings report and execution on defense/aerospace partnerships, but investors face substantial risk from cash burn and market volatility in the semiconductor sector.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →